Business
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
EQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024 EQ302, an orally delivered multi-cytokine inhibitor of IL-15 &
About this update from Equillium, Inc.
[{"type":"text","content":"\nEQ101 Phase 2 study in alopecia areata is fully enrolled with topline data expected in Q2 2024\n\n\nEQ302, an orally delivered multi-cytokine inhibitor of IL-15 & IL-21, will be advanced in place of further clinical development of EQ102 based on EQ302’s optimal delivery and increased potency\n\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced an update on multi-cytokine programs EQ101 in development for the treatment of alopecia areata, EQ102 in development for the treatment of celiac disease, and EQ302, a new orally delivered multi-cytokine inhibitor.\n\n\n“We are pleased to have completed enrollment of the EQ101 Phase 2 study in alopecia areata,” said Bruce Steel, chief executive officer at Equillium. “We have enrolled a total of 36 patients in the study, of which 13, or 36 percent, had very severe alopecia areata. These patients are in need of new treatments that may have an improved safety profile compared to recently approved JAK inhibitors. While the study remains ongoing, to date EQ101 has been well tolerated over the 24-week dosing period. We expect to announce top-line data in Q2 2024.”\n\n\nEQ101 Alopecia Areata Phase 2 Study Baseline Characteristics:\n\n\n\n36 patients enrolled:\n\n\n17 male and 19 female; 64% Caucasian\n\n\n\nAge range of 18 to 60 years (mean age 38.2 years)\n\n\n\n\n\n\nDisease severity of patients at enrollment as defined by Severity of ALopecia Tool (SALT):\n\n\nMean SALT score of 76\n\n\n\n17% Moderate (SALT score 35 to 49)\n\n\n\n50% Severe (SALT score 50 to 94)\n\n\n\n33% Very Severe (SALT score > 95%)\n\n\n\n\n\n\n27 patients (75%) had been on previous treatments with 11 of those patients having history of oral treatments (including steroids, minoxidil, methotrexate, mycophenolate mofetil) and one patient having previous treatment with a systemic JAK inhibitor\n\n\n\nEQ102 & EQ302\n\n\n“EQ102 is a first-in-class, bi-specific inhibitor of IL-15 and IL-21, two cytokines central to T and B cell activity, that exhibit biological synergy driving aggressive inflammatory responses in a number of gastrointestinal and skin diseases, highlighting the importance of dual inhibition,” said Steve Connelly, chief scientific officer at Eq...